$111.42
▲ +0.8% Today
as of Jul 22, 16:53 ET
Last 30 days
Recent Press Releases & News
Revvity to Launch Signals for Startups for Emerging Biotech Companies
RVTY: Lowering target price to $116.00
Revvity Releases 2026 Impact Report Advancing Transparency with Initial Scope 3 Emissions Disclosure
Overview
52-week range
$81
$118
81% of range
Avg surprise (last 3)
+4.2%
Avg reaction (last 2)
+3.8%
100% positive
Latest IV / EM
51%
EM ±11.8% · $110 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 5, 2026 | Mar/2026 | $1.06 | $1.02 | +3.9% | +5.0% | +6.7% | earnings |
| Sun Sep 28, 2025 | Sep 2025 | $0.40 | — | — | — | — | financials |
| Mon Jul 28, 2025 | Jun/2025 | $1.18 | $1.14 | +3.5% | — | — | earnings |
| Mon Apr 28, 2025 | Mar/2025 | $1.01 | $0.96 | +5.2% | — | +0.8% | earnings |
| Sun Sep 29, 2024 | Sep 2024 | $0.77 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $0.45 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $0.21 | — | — | — | — | financials |
| Sun Oct 1, 2023 | Oct 2023 | $0.08 | — | — | — | — | financials |
| Sun Jul 2, 2023 | Jul 2023 | $0.28 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Aug 4, 2026 | Jun/2026 | BMO | $1.23 | $1.18 | +4.2% |
Financials
Income statement (quarterly)
| Metric | Apr 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $76M | — | $82M | $91M | $72M | — | $98M | $86M |
| Net income | $41M | — | $47M | $54M | $42M | — | $94M | $55M |
| EPS (diluted) | $0.36 | — | $0.40 | $0.46 | $0.35 | — | $0.77 | $0.45 |
Balance sheet (quarterly)
| Metric | Apr 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $860M | $920M | $931M | $992M | $1.14B | $1.16B | $1.23B | $1.25B |
| Inventory | $388M | $379M | $380M | $388M | $381M | $368M | $405M | $401M |
| Total current assets | $2.13B | $2.24B | $2.14B | $2.24B | $2.32B | $2.35B | $2.45B | $3.16B |
| Total assets | $12.00B | $12.17B | $12.14B | $12.36B | $12.36B | $12.39B | $12.77B | $13.42B |
| Long-term debt | $2.63B | $2.63B | $2.63B | $3.21B | $3.17B | $3.15B | $3.19B | $3.16B |
| Total liabilities | $4.81B | $4.92B | $4.76B | $4.81B | $4.72B | $4.73B | $4.85B | $5.55B |
| Total equity | $7.18B | $7.25B | $7.38B | $7.56B | $7.64B | $7.67B | $7.92B | $7.87B |